CannTrust Partners with McMaster University on Medicinal Cannabis Research For Chronic Pain

Cannabis Investing News

CannTrust Holdings (TSX:TRST) has announced a collaboration with Hamilton Health Sciences and McMaster Univesrity for medical research studies. As quoted in the press release: Hamilton Health Sciences and McMaster are known world-wide for innovation in education and research, and for its role in developing evidence-based medicine. This partnership strengthens CannTrust’s existing commitment to innovation and its contribution …

CannTrust Holdings (TSX:TRST) has announced a collaboration with Hamilton Health Sciences and McMaster Univesrity for medical research studies.

As quoted in the press release:

Hamilton Health Sciences and McMaster are known world-wide for innovation in education and research, and for its role in developing evidence-based medicine. This partnership strengthens CannTrust’s existing commitment to innovation and its contribution to generating evidence regarding the therapeutic use and clinical effectiveness of cannabinoids.

CannTrust will be working with the Michael G. DeGroote Pain Clinic of Hamilton Health Sciences and McMaster University, and the Michael G. DeGroote Institute for Pain Research and Care of McMaster University on a range of upcoming randomized placebo controlled clinical trials (RCT), representing the first Canadian University partnership for the Company. Utilizing CannTrust’s broad range of quality cannabis products, the first clinical trial, Cannabis Oil for Chronic Non-Cancer Pain Treatment (CONCEPT), is expected to begin this fall, with additional studies to follow.

The results of these studies will be crucial for researchers, health care practitioners and policy makers to use cannabinoids for designing more effective, safer treatment protocols and public health policies. Throughout the partnership, CannTrust will utilize its more than 40 years of pharmacy, healthcare experience and knowledge to help McMaster and Hamilton Health Sciences study the application of the Company’s products as treatment for various patient needs.

An analysis of CannTrust’s 48,000 existing customer profiles indicates that pain is one of the primary reasons for utilizing medical cannabis, highlighting the need for trials in this area. Through research at the Centre, CannTrust aims to help healthcare professionals and patients better understand the possible benefits of medical cannabis for those living with pain-related conditions, and beyond.

Click here to read the full press release.

The Conversation (0)
Ă—